Get the Stockscreener App
4.73
0.21%
0.00
Y Mabs Therapeutics Inc stock is traded at $4.73, with a volume of 15,305.
It is up +0.21% in the last 24 hours and down -24.04% over the past month.
Y-mAbs Therapeutics Inc is a commercial-stage biopharmaceutical company. It is mainly engaged in the development and commercialization of novel, antibody-based therapeutic products for the treatment of cancer. DANYELZA, is the first FDA-approved product of the company which is a recombinant humanized immunoglobulin G, subtype 1k, or IgG1k, monoclonal antibody or mAb that targets ganglioside GD2, which is expressed in various neuroectoderm-derived tumors and sarcomas.
See More
Previous Close:
$4.73
Open:
$4.77
24h Volume:
15,305
Relative Volume:
0.04
Market Cap:
$215.92M
Revenue:
$84.82M
Net Income/Loss:
$-21.43M
P/E Ratio:
-9.6531
EPS:
-0.49
Net Cash Flow:
$-27.23M
1W Performance:
-8.14%
1M Performance:
-24.04%
6M Performance:
-65.50%
1Y Performance:
-68.40%
1-Day Range:
$4.725
$4.86
1-Week Range:
$4.62
$5.08
52-Week Range:
$4.57
$17.78
Y Mabs Therapeutics Inc Stock (YMAB) Company Profile
Name
Y Mabs Therapeutics Inc
Sector
Industry
Phone
646-885-8505
Address
202 CARNEGIE CENTER, PRINCETON, NY
Compare YMAB with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
YMAB
Y Mabs Therapeutics Inc
|
4.73 | 215.92M | 84.82M | -21.43M | -27.23M | -0.49 |
|
VRTX
Vertex Pharmaceuticals Inc
|
509.02 | 130.68B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
679.48 | 74.97B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
597.00 | 36.08B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
241.57 | 31.19B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
256.79 | 27.56B | 3.32B | -860.46M | -1.04B | -8.32 |
Y Mabs Therapeutics Inc Stock (YMAB) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Nov-18-24 | Initiated | Oppenheimer | Outperform |
| Aug-16-24 | Initiated | Cantor Fitzgerald | Overweight |
| Jun-28-24 | Initiated | Truist | Buy |
| May-10-23 | Upgrade | Wedbush | Neutral → Outperform |
| Apr-03-23 | Downgrade | Guggenheim | Buy → Neutral |
| Jan-27-23 | Downgrade | Morgan Stanley | Equal-Weight → Underweight |
| Jan-05-23 | Downgrade | Cowen | Outperform → Market Perform |
| Dec-02-22 | Downgrade | BofA Securities | Buy → Neutral |
| Oct-31-22 | Downgrade | JP Morgan | Neutral → Underweight |
| Oct-31-22 | Downgrade | Wedbush | Outperform → Neutral |
| Jul-06-22 | Resumed | Canaccord Genuity | Buy |
| Jun-24-22 | Initiated | BMO Capital Markets | Outperform |
| Feb-03-22 | Resumed | Guggenheim | Buy |
| Nov-19-21 | Resumed | Morgan Stanley | Equal-Weight |
| Nov-16-21 | Downgrade | JP Morgan | Overweight → Neutral |
| May-07-21 | Upgrade | BofA Securities | Neutral → Buy |
| Apr-23-21 | Resumed | Cowen | Outperform |
| Mar-22-21 | Resumed | JP Morgan | Overweight |
| Jan-15-21 | Downgrade | BofA Securities | Buy → Neutral |
| Nov-09-20 | Reiterated | H.C. Wainwright | Buy |
| May-05-20 | Initiated | Barclays | Overweight |
| May-01-20 | Initiated | Janney | Buy |
| Apr-29-20 | Initiated | Morgan Stanley | Equal-Weight |
| Dec-24-19 | Initiated | JP Morgan | Overweight |
| Nov-20-19 | Initiated | Guggenheim | Buy |
| Sep-04-19 | Initiated | Wedbush | Outperform |
| Apr-01-19 | Initiated | H.C. Wainwright | Buy |
| Oct-16-18 | Initiated | BTIG Research | Buy |
| Oct-16-18 | Initiated | BofA/Merrill | Buy |
View All
Y Mabs Therapeutics Inc Stock (YMAB) Latest News
12 Health Care Stocks Moving In Thursday's Pre-Market Session - Benzinga
Y-mabs therapeutics CEO Michael Rossi sells $20,368 in stock - Investing.com
Y-mabs therapeutics CBO Gad Thomas sells $56,536 in stock - Investing.com
Y-mAbs Therapeutics Executives Sell Shares - TradingView
Y-mAbs Therapeutics, Inc. (YMAB) Reports Q4 Loss, Lags Revenue Estimates - MSN
YMAB Q1 EPS Estimate Boosted by Brookline Capital Management - MarketBeat
Bearish: Analysts Just Cut Their Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB) Revenue and EPS estimates - Yahoo Finance UK
FY2025 EPS Estimates for YMAB Reduced by Cantor Fitzgerald - Defense World
Wedbush Reduces Earnings Estimates for Y-mAbs Therapeutics - Defense World
From Clinical Trials to the Market: Cancer Stocks With Big Potential in 2025 - Baystreet.ca
Y-mAbs Therapeutics, Inc. to Host Earnings Call - ACCESS Newswire
Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB) Just Reported And Analysts Have Been Cutting Their Estimates - Simply Wall St
Bank of America Lowers Y-mAbs Therapeutics (NASDAQ:YMAB) Price Target to $12.00 - Defense World
Morgan Stanley Issues Pessimistic Forecast for Y-mAbs Therapeutics (NASDAQ:YMAB) Stock Price - Defense World
Truist Financial Has Lowered Expectations for Y-mAbs Therapeutics (NASDAQ:YMAB) Stock Price - Defense World
Forecasting The Future: 4 Analyst Projections For Y-mAbs Therapeutics - Benzinga
Y-mAbs Therapeutics price target lowered to $12 from $14 at BofA - TipRanks
Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB) Q4 2024 Earnings Call Transcript - Insider Monkey
Truist Cuts Price Target on Y-mAbs Therapeutics to $18 From $21, Keeps Buy Rating -March 05, 2025 at 06:27 am EST - Marketscreener.com
Y-mAbs Therapeutics Inc (YMAB) Q4 2024 Earnings Call Highlights: Strategic Realignment and ... By GuruFocus - Investing.com Canada
Y-mAbs Therapeutics Reports 2024 Financial Results - TipRanks
Y-mAbs Therapeutics’ Earnings Call Highlights Mixed Results - TipRanks
Y-mAbs Therapeutics inks equity deal up to $35M - Investing.com India
Y-mAbs Therapeutics Inc Enters Equity Distribution Agreement With Oppenheimer -March 04, 2025 at 04:32 pm EST - Marketscreener.com
Y-mAbs Therapeutics inks equity deal up to $35M By Investing.com - Investing.com UK
SEC Form 424B5 filed by Y-mAbs Therapeutics Inc. - Quantisnow
Y-mAbs stock price target cut to $19 at Cantor Fitzgerald - Investing.com UK
Wedbush Cuts Price Target on Y-mAbs Therapeutics to $21 From $23, Keeps Outperform Rating - Marketscreener.com
Y-mAbs Therapeutics Inc reports results for the quarter ended December 31Earnings Summary - TradingView
Y-mAbs Therapeutics (NASDAQ:YMAB) shareholders have endured a 79% loss from investing in the stock five years ago - Yahoo Finance
Y-mAbs announces publication of Phase 2 interim results on naxitamab - Yahoo Finance
Y-mAbs Therapeutics Reports Fourth Quarter 2024 Financial Results - TradingView
Y-mAbs Reports Fourth Quarter 2024 Financial Results -March 04, 2025 at 07:06 am EST - Marketscreener.com
Y-mAbs Reports Fourth Quarter 2024 Financial Results and Recent Corporate Developments - The Manila Times
Y-mAbs Therapeutics reports Q4 EPS (15c), consensus (13c) - TipRanks
Y-mAbs Therapeutics (NASDAQ:YMAB) Given “Outperform” Rating at Wedbush - Defense World
Leptomeningeal Metastases Market Anticipated to Expand - openPR
Naxitamab shows promise in neuroblastoma phase 2 trial - Investing.com
Y-mAbs Announces Publication of Phase 2 Interim Results in Nature Communications - The Manila Times
Y-mAbs Therapeutics Publishes Positive Interim Data on Naxitamab for High-Risk Neuroblastoma in Nature Communications - Nasdaq
Can Y-mAbs' Neuroblastoma Therapy Turn 93% Survival Rate Into FDA Approval? - StockTitan
How the (YMAB) price action is used to our Advantage - Stock Traders Daily
YMAB CLASS ACTION: Hagens Berman, National Trial Attorneys, Encourages Y-mAbs Therapeutics (YMAB) Investors with Significant Losses to Contact Firm’s Attorneys, Securities Fraud Lawsuit Filed - ACCESS Newswire
Y MABS THERAPEUTICS Earnings Preview: Recent $YMAB Insider Trading, Hedge Fund Activity, and More - Nasdaq
Y-mAbs Therapeutics (YMAB) Expected to Announce Earnings on Tuesday - Defense World
Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB) Receives Average Recommendation of “Buy” from Brokerages - Defense World
Y-mAbs Therapeutics (YMAB) to Release Earnings on Tuesday - MarketBeat
Shareholders in Y-mAbs Therapeutics (NASDAQ:YMAB) are in the red if they invested five years ago - Simply Wall St
Y-mAbs Therapeutics, Inc. (YMAB) Expected to Beat Earnings Estimates: What to Know Ahead of Q4 Release - Yahoo Finance
Y-mAbs to Announce Fourth Quarter and Full Year 2024 Financial and Operating Results on March 4, 2025 - Taiwan News
Y-mAbs Therapeutics, Inc. to Announce Fourth Quarter and Full Year 2024 Results on March 4, 2025 - Nasdaq
Y Mabs Therapeutics Inc Stock (YMAB) Financials Data
Revenue
Net Income
Cash Flow
EPS
Y Mabs Therapeutics Inc Stock (YMAB) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Gad Thomas | CHIEF BUSINESS OFFICER |
Mar 07 '25 |
Sale |
5.23 |
10,810 |
56,536 |
202,721 |
1.28%
0.80%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):